<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04767815</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWN12088102</org_study_id>
    <nct_id>NCT04767815</nct_id>
  </id_info>
  <brief_title>To Evaluate Food Effect on the PK and Safety After Oral DWN12088 Administration in Healthy Adult Volunteers</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics and Safety After Oral DWN12088 Administration in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The pharmacokinetics (PK) and safety of single oral dose of DWN12088 in healthy adults will&#xD;
      be compared and assessed on an empty stomach, after high-fat meal, or 2 hours after high-fat&#xD;
      meal.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pharmacokinetics and safety of single oral dose of DWN12088 in healthy adults will be&#xD;
      compared and assessed on an empty stomach, after high-fat meal, or 2 hours after high-fat&#xD;
      meal.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 22, 2021</start_date>
  <completion_date type="Actual">June 4, 2021</completion_date>
  <primary_completion_date type="Actual">May 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of DWN12088 and metabolite</measure>
    <time_frame>Day 1, Day8 and Day15 of 0 hours, 0.5 hours, 1 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours</time_frame>
    <description>To evaluate pharmacokinetics parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of DWN12088 and metabolite</measure>
    <time_frame>Day 1, Day8 and Day15 of 0 hours, 0.5 hours, 1 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours</time_frame>
    <description>To evaluate pharmacokinetics parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events (AEs) such as subjective and objective symptoms</measure>
    <time_frame>follow-up 26 days after dosing</time_frame>
    <description>To evaluate safety</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf of DWN12088 and metabolite</measure>
    <time_frame>Day 1, Day8 and Day15 of 0 hours, 0.5 hours, 1 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours</time_frame>
    <description>To evaluate pharmacokinetics parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of DWN12088 and metabolite</measure>
    <time_frame>Day 1, Day8 and Day15 of 0 hours, 0.5 hours, 1 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours</time_frame>
    <description>To evaluate pharmacokinetics parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of DWN12088 and metabolite</measure>
    <time_frame>Day 1, Day8 and Day15 of 0 hours, 0.5 hours, 1 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours</time_frame>
    <description>To evaluate pharmacokinetics parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of DWN12088 and metabolite</measure>
    <time_frame>Day 1, Day8 and Day15 of 0 hours, 0.5 hours, 1 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours</time_frame>
    <description>To evaluate pharmacokinetics parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of DWN12088 and metabolite</measure>
    <time_frame>Day 1, Day8 and Day15 of 0 hours, 0.5 hours, 1 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours</time_frame>
    <description>To evaluate pharmacokinetics parameter</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: A (Fasting)&#xD;
Period 2: B (30 minutes after a High-fat meal)&#xD;
Period 3: C (2 hours after a High-fat meal)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: B (30 minutes after a High-fat meal)&#xD;
Period 2: C (2 hours after a High-fat meal)&#xD;
Period 3: A (Fasting)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: C (2 hours after a High-fat meal)&#xD;
Period 2: A (Fasting)&#xD;
Period 3: B (30 minutes after a High-fat meal)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: A (Fasting)&#xD;
Period 2: C (2 hours after a High-fat meal)&#xD;
Period 3: B (30 minutes after a High-fat meal)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: C (2 hours after a High-fat meal)&#xD;
Period 2: B (30 minutes after a High-fat meal)&#xD;
Period 3: A (Fasting)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: B (30 minutes after a High-fat meal)&#xD;
Period 2: A (Fasting)&#xD;
Period 3: C (2 hours after a High-fat meal)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diet A group</intervention_name>
    <description>Fasting + DWN12088 200 mg</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diet B group</intervention_name>
    <description>30 minutes after a high-fat meal + DWN12088 200 mg</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diet C group</intervention_name>
    <description>2 hours after a high-fat meal + DWN12088 200 mg</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adults aged ≥ 19 and ≤ 55 years at screening&#xD;
&#xD;
          2. Subjects with body weight ≥ 55.0 kg (male) or ≥ 45.0 kg (female) with a body mass&#xD;
             index (BMI) of ≥ 18.0 kg/m2 to &lt; 27.0 kg/m2 at screening test&#xD;
&#xD;
             ☞ BMI (kg/m2) = Body weight (kg) / {Height (m)}2&#xD;
&#xD;
          3. Subjects who have given written consent on voluntary decision of participation prior&#xD;
             to the screening procedure after being fully informed of and completely understanding&#xD;
             this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with current or history of clinically significant hematological disorder,&#xD;
             tumor, or immunologic, endocrine, psychiatric, neurological, cardiovascular,&#xD;
             respiratory, digestive, hepatobiliary, renal, or urinary disorder&#xD;
&#xD;
          2. Subjects with a history of a gastrointestinal disorder (gastrointestinal ulcers,&#xD;
             gastritis, stomach cramps, gastroesophageal reflux disease, Crohn's disease, etc.) or&#xD;
             surgery (except for simple appendectomy or hernia surgery) that may affect the safety&#xD;
             and PK assessment of the investigational product (IP)&#xD;
&#xD;
          3. Subjects with clinically significant hypersensitivity to any drugs including the&#xD;
             ingredient of the IP (DWN12088) or excipients&#xD;
&#xD;
          4. Subjects determined ineligible for meeting the one of the following on the screening&#xD;
             tests conducted within 28 days prior to administration of the IP administration&#xD;
&#xD;
             ① AST or ALT &gt; 1.5 times the upper limit of normal&#xD;
&#xD;
               -  Estimated glomerular filtration rate (eGFR) &lt; 90 mL/min/1.73 m2 based on the&#xD;
                  modification of diet in renal disease (MDRD) formula ③ QTc interval &gt; 450 ms ④&#xD;
                  Positive result in serology (hepatitis B tests, hepatitis C tests, human&#xD;
                  immunodeficiency virus [HIV] tests, syphilis tests) ⑤ Sitting systolic blood&#xD;
                  pressure &gt; 150 mmHg or &lt; 90 mmHg or sitting diastolic blood pressure &gt; 100 mmHg&#xD;
                  or &lt; 50 mmHg after resting for more than 3 minutes&#xD;
&#xD;
          5. Subjects with a history of drug abuse or positive result of using abusive drugs in&#xD;
             urine drug screening test within 1 year prior to screening&#xD;
&#xD;
          6. Subjects who used any prescription drugs or herbal medicines within 14 days, or any&#xD;
             over-the-counter (OTC) drugs including dietary supplements and vitamin supplements&#xD;
             within 7 days prior to the first dose of the IP which are judged to impact the study&#xD;
             or the subject's safety by the investigator&#xD;
&#xD;
          7. Subjects who participated in another clinical study and received another IP within 180&#xD;
             days before the first dose of the IP&#xD;
&#xD;
          8. Subjects who donated whole blood within 60 days, donated blood components within 30&#xD;
             days, or received blood transfusion within 30 days prior to the first dose of the IP&#xD;
&#xD;
          9. Subjects who consistently consumed excessive amount of caffein or alcohol (caffein &gt; 5&#xD;
             cups/day, alcohol &gt; 210 g/week) or are unable to refrain from caffein or alcohol&#xD;
             intake from 3 days before the first dose to the post study visit (PSV)&#xD;
&#xD;
         10. Subjects who are current smokers (may be selected as subjects if they stopped smoking&#xD;
             more than 180 days prior to the first dose of the IP) or unable to stop smoking from&#xD;
             180 days prior to the first dose of the IP to the PSV&#xD;
&#xD;
         11. Subjects who used drugs inducing and inhibiting drug-metabolizing enzymes, such as&#xD;
             barbital drugs, within 30 days prior to the first dose of the IP&#xD;
&#xD;
         12. Subjects who consumed grapefruit, grapefruit juice, or grapefruit-containing products&#xD;
             from 3 days prior to the first hospitalization to the last discharge of period 3, or&#xD;
             are unable to refrain from the intake of grapefruit-containing products during this&#xD;
             period&#xD;
&#xD;
         13. Subjects who are on or plan to receive CYP2D6 inducing/inhibiting drugs&#xD;
&#xD;
         14. Female subjects who are pregnant or lactating&#xD;
&#xD;
             ① All female subjects with childbearing potential except for those who are menopausal&#xD;
             or surgically sterile (hysterectomy, bilateral tubal ligation, or bilateral&#xD;
             oophorectomy), who have a positive pregnancy test (serum hCG or urine hCG)&#xD;
&#xD;
         15. Subjects or their spouses or partners who are unable to use medically acceptable&#xD;
             appropriate double-method of contraception or medically acceptable contraception&#xD;
             throughout the study period and for at least 4 weeks after the last IP administration,&#xD;
             and disagreed to refrain from donating sperms during this period&#xD;
&#xD;
               -  Caution: Woman of childbearing potential is defined as a woman who is not&#xD;
                  surgically sterile or post-menopausal. Women amenorrhoeic for 12 months without&#xD;
                  an alternative medical cause will be considered as post-menopausal.&#xD;
&#xD;
               -  Medically acceptable methods of contraception ① Use of intrauterine device&#xD;
                  (except for copper banded coil and hormonal device) for which pregnancy failure&#xD;
                  rate is proven, by a subject or spouse (or partner) ② Physical and chemical&#xD;
                  barrier contraception (male/female condom with spermicide, diaphragm, sponge,&#xD;
                  cervical cap with spermicide, etc.) ③ Surgical sterilization (vasectomy,&#xD;
                  salpingectomy, tubal ligation, and hysterectomy) of a subject or spouse (or&#xD;
                  partner)&#xD;
&#xD;
         16. Subjects determined to be ineligible to participate in the study by the investigator&#xD;
             due to reasons other than those specified above&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaeseong Oh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 15, 2021</study_first_submitted>
  <study_first_submitted_qc>February 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2021</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

